Syringe demonstrates cost benefits of sustainable design
Cambridge Consultants unveils an innovative concept for prefilled syringes, cutting pack volume in half.
Instead of glass, Syreen syringes are made from cyclic olefin polymer (COP) plastic, which means there is no need for secondary packaging. The company claims it is a first in this area of medical devices.
The makeup of the Syreen allows syringes to clip together, nesting in a pack, while the COP design doubles as the outer shell of the packaging itself. There is no need, therefore, for fillers such as cardboard and styrofoam, reducing the packaging weight by 30% and volume by 50% compared with standard packaging.
"This marriage of economy and ecology shows that medical device companies will likely see competitive benefits by taking sustainability seriously," said Phil Lever, commercial director, Drug Delivery Devices for pharma technology firm Cambridge Consultants, which has offices in Cambridge in the UK and US.
To use Syreen, the prefilled syringe is simply unclipped and put against the desired area on the skin. After delivery, with a simple snap, the user ejects the needle into the sharps bin, allowing the user to recycle the plastic capsule.
Patient safety is further increased because the COP plastic syringe features a curved surface over the needle that, while keeping the syringe from rolling and reducing needle-stick accidents, also ensures overall stability and depth control during injection. With separated plunger and stopper, the design also makes it impossible to take in blood or other contaminants, reducing the risk of cross infection.
Cambridge Consultants is currently seeking to develop the Syreen concept with large pharmaceutical and pharmaceutical packaging companies.
You may also like
Trending Articles
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Packaging
Aspirations for better pack design
As manufacturers look to provide treatments for the long-term management of increasingly complex diseases and medical conditions, Cambridge Consultants discusses the role of design in meeting the needs of an ageing population and the trend towards self-medication by patients at home
Drug Delivery
Challenges and development perspectives of primary packaging for parenteral drugs
When talking about parenteral drugs, we usually refer to the administration of drugs by injection through the integument or directly into the circulation, says Andrea Sentimenti, Marketing & Innovation Director at Bormioli Pharma. The parenteral route – it could be intradermal, subcutaneous, intramuscular or intravenous – indeed allows a rapid effect, the administration of orally inactivated drugs, rapid intervention in emergencies, and the administration of nutritional solutions to patients who cannot feed themselves normally